{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:04:20Z","timestamp":1783811060980,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"McCabe Foundation","award":["ITMAT-UL1TR001878"],"award-info":[{"award-number":["ITMAT-UL1TR001878"]}]},{"name":"McCabe Foundation","award":["R01CA250102"],"award-info":[{"award-number":["R01CA250102"]}]},{"name":"McCabe Foundation","award":["R01CA228457"],"award-info":[{"award-number":["R01CA228457"]}]},{"name":"McCabe Foundation","award":["R01CA268601"],"award-info":[{"award-number":["R01CA268601"]}]},{"name":"University of Pennsylvania","award":["ITMAT-UL1TR001878"],"award-info":[{"award-number":["ITMAT-UL1TR001878"]}]},{"name":"University of Pennsylvania","award":["R01CA250102"],"award-info":[{"award-number":["R01CA250102"]}]},{"name":"University of Pennsylvania","award":["R01CA228457"],"award-info":[{"award-number":["R01CA228457"]}]},{"name":"University of Pennsylvania","award":["R01CA268601"],"award-info":[{"award-number":["R01CA268601"]}]},{"name":"NIH grants","award":["ITMAT-UL1TR001878"],"award-info":[{"award-number":["ITMAT-UL1TR001878"]}]},{"name":"NIH grants","award":["R01CA250102"],"award-info":[{"award-number":["R01CA250102"]}]},{"name":"NIH grants","award":["R01CA228457"],"award-info":[{"award-number":["R01CA228457"]}]},{"name":"NIH grants","award":["R01CA268601"],"award-info":[{"award-number":["R01CA268601"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer is a multi-focal disease that can be treated using surgery, radiation, androgen deprivation, and chemotherapy, depending on its presentation. Standard dose-escalated radiation therapy (RT) in the range of 70\u201380 Gray (GY) is a standard treatment option for prostate cancer. It could be used at different phases of the disease (e.g., as the only primary treatment when the cancer is confined to the prostate gland, combined with other therapies, or as an adjuvant treatment after surgery). Unfortunately, RT for prostate cancer is associated with gastro-intestinal and genitourinary toxicity. We have previously reported that the metabolic modulator lonidamine (LND) produces cancer sensitization through tumor acidification and de-energization in diverse neoplasms. We hypothesized that LND could allow lower RT doses by producing the same effect in prostate cancer, thus reducing the detrimental side effects associated with RT. Using the Seahorse XFe96 and YSI 2300 Stat Plus analyzers, we corroborated the expected LND-induced intracellular acidification and de-energization of isolated human prostate cancer cells using the PC3 cell line. These results were substantiated by non-invasive 31P magnetic resonance spectroscopy (MRS), studying PC3 prostate cancer xenografts treated with LND (100 mg\/kg, i.p.). In addition, we found that LND significantly increased tumor lactate levels in the xenografts using 1H MRS non-invasively. Subsequently, LND was combined with radiation therapy in a growth delay experiment, where we found that 150 \u00b5M LND followed by 4 GY RT produced a significant growth delay in PC3 prostate cancer xenografts, compared to either control, LND, or RT alone. We conclude that the metabolic modulator LND radio-sensitizes experimental prostate cancer models, allowing the use of lower radiation doses and diminishing the potential side effects of RT. These results suggest the possible clinical translation of LND as a radio-sensitizer in patients with prostate cancer.<\/jats:p>","DOI":"10.3390\/cancers16071384","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:28:00Z","timestamp":1711891680000},"page":"1384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Stepan","family":"Orlovskiy","sequence":"first","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-3899","authenticated-orcid":false,"given":"Pradeep Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Roman","sequence":"additional","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Arias-Mendoza","sequence":"additional","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"},{"name":"Advanced Imaging Research, Inc., Cleveland, OH 44114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5993-8710","authenticated-orcid":false,"given":"David S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Putt","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-5703","authenticated-orcid":false,"given":"Kavindra","family":"Nath","sequence":"additional","affiliation":[{"name":"Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"1288","article-title":"NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2014A Systematic Review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_4","unstructured":"Jain, M.A., Leslie, S.W., and Sapra, A. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2147\/PPA.S362802","article-title":"Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review","volume":"16","author":"Menges","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up","volume":"379","author":"Holmberg","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of Prostatectomy versus Observation for Early Prostate Cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Posdzich, P., Darr, C., Hilser, T., Wahl, M., Herrmann, K., Hadaschik, B., and Grunwald, V. (2023). Metastatic Prostate Cancer-A Review of Current Treatment Options and Promising New Approaches. Cancers, 15.","DOI":"10.3390\/cancers15020461"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.3390\/curroncol30090587","article-title":"The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer","volume":"30","author":"Numakura","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"688394","DOI":"10.3389\/fsurg.2021.688394","article-title":"Management of Medium and Long Term Complications Following Prostate Cancer Treatment Resulting in Urinary Diversion - A Narrative Review","volume":"8","author":"Hoeh","year":"2021","journal-title":"Front. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/nbm.3240","article-title":"Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin","volume":"28","author":"Nath","year":"2015","journal-title":"NMR Biomed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/nbm.2824","article-title":"(31) P and (1) H MRS of DB-1 melanoma xenografts: Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan","volume":"26","author":"Nath","year":"2013","journal-title":"NMR Biomed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14654","DOI":"10.1038\/s41598-018-33019-4","article-title":"Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin","volume":"8","author":"Nath","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","article-title":"The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters","volume":"473","author":"Nancolas","year":"2016","journal-title":"Biochem. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1074\/jbc.M115.697516","article-title":"Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine","volume":"291","author":"Guo","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_22","first-page":"497","article-title":"Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells","volume":"66","author":"Floridi","year":"1981","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1358\/dot.2003.39.3.799451","article-title":"Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors","volume":"39","author":"Ferretti","year":"2003","journal-title":"Drugs Today"},{"key":"ref_24","first-page":"151","article-title":"Mechanism of antineoplastic activity of lonidamine","volume":"1866","author":"Nath","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/mrm.21659","article-title":"Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical-shift imaging","volume":"60","author":"Pickup","year":"2008","journal-title":"Magn. Reson. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/bjc.1995.431","article-title":"The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours","volume":"72","author":"McCoy","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/nbm.1940050606","article-title":"An assessment of 31P MRS as a method of measuring pH in rat tumours","volume":"5","author":"Stubbs","year":"1992","journal-title":"NMR Biomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0360-3016(97)00073-4","article-title":"Radiation-induced apoptosis in different pH environments in vitro","volume":"38","author":"Lee","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","first-page":"54","article-title":"Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy","volume":"1","author":"Efron","year":"1986","journal-title":"Stat. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2307\/3577209","article-title":"Lonidamine-induced, pH dependent inhibition of cellular oxygen utilization","volume":"113","author":"Stryker","year":"1988","journal-title":"Radiat. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.cdd.4400702","article-title":"Cell cycle progression and apoptosis after irradiation in an acidic environment","volume":"7","author":"Park","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1667\/0033-7587(2003)159[0086:IOEPOG]2.0.CO;2","article-title":"Influence of environmental pH on G2-phase arrest caused by ionizing radiation","volume":"159","author":"Park","year":"2003","journal-title":"Radiat. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000225883","article-title":"Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine","volume":"41","author":"Kim","year":"1984","journal-title":"Oncology"},{"key":"ref_34","first-page":"1120","article-title":"Potentiation of radiation effects on two murine tumors by lonidamine","volume":"46","author":"Kim","year":"1986","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1984.232","article-title":"Inhibition of the recovery from potentially lethal damage by lonidamine","volume":"50","author":"Hahn","year":"1984","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0360-3016(91)90063-A","article-title":"The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines","volume":"20","author":"Raaphorst","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10495-017-1424-9","article-title":"Induction of reactive oxygen species: An emerging approach for cancer therapy","volume":"22","author":"Zou","year":"2017","journal-title":"Apoptosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/35037717","article-title":"Defying death after DNA damage","volume":"407","author":"Rich","year":"2000","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0360-3016(94)90225-9","article-title":"Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer","volume":"29","author":"Magno","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000225898","article-title":"Lonidamine and radiotherapy in head and neck cancers. A pilot study","volume":"41","author":"Magno","year":"1984","journal-title":"Oncology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0360-3016(94)90394-8","article-title":"A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer","volume":"29","author":"Scarantino","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","first-page":"436","article-title":"Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer","volume":"41","author":"Gatzemeier","year":"1991","journal-title":"Arzneimittelforschung"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.1991.356","article-title":"A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer","volume":"64","author":"Mansi","year":"1991","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002800050460","article-title":"Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs","volume":"38","author":"Price","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nantod.2017.02.008","article-title":"Peptide nanoparticle with pH-sensing cargo solubility enhances cancer drug efficiency","volume":"13","author":"Nath","year":"2017","journal-title":"Nano Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/s41467-019-10042-1","article-title":"Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:21:55Z","timestamp":1760106115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,31]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071384"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071384","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,31]]}}}